Literature DB >> 25480507

Mechanism-based inhibitors of glycosidases: design and applications.

Wouter W Kallemeijn1, Martin D Witte2, Tom Wennekes3, Johannes M F G Aerts4.   

Abstract

This article covers recent developments in the design and application of activity-based probes (ABPs) for glycosidases, with emphasis on the different enzymes involved in metabolism of glucosylceramide in humans. Described are the various catalytic reaction mechanisms employed by inverting and retaining glycosidases. An understanding of catalysis at the molecular level has stimulated the design of different types of ABPs for glycosidases. Such compounds range from (1) transition-state mimics tagged with reactive moieties, which associate with the target active site—forming covalent bonds in a relatively nonspecific manner in or near the catalytic pocket—to (2) enzyme substrates that exploit the catalytic mechanism of retaining glycosidase targets to release a highly reactive species within the active site of the enzyme, to (3) probes based on mechanism-based, covalent, and irreversible glycosidase inhibitors. Some applications in biochemical and biological research of the activity-based glycosidase probes are discussed, including specific quantitative visualization of active enzyme molecules in vitro and in vivo, and as strategies for unambiguously identifying catalytic residues in glycosidases in vitro.
© 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acid/base; Activity-based probes; Cyclophellitol; Cyclophellitol aziridine; Diagnostics; Enzyme replacement therapy; Epoxide; Fluorescent; Fluoroglycosides; GBA; Gaucher; Glucocerebrosidase; Glycosidases; Nucleophile; Retaining; β-Glucosidase

Mesh:

Substances:

Year:  2014        PMID: 25480507     DOI: 10.1016/B978-0-12-800128-8.00004-2

Source DB:  PubMed          Journal:  Adv Carbohydr Chem Biochem        ISSN: 0065-2318            Impact factor:   12.200


  8 in total

1.  Distinguishing the differences in β-glycosylceramidase folds, dynamics, and actions informs therapeutic uses.

Authors:  Fredj Ben Bdira; Marta Artola; Herman S Overkleeft; Marcellus Ubbink; Johannes M F G Aerts
Journal:  J Lipid Res       Date:  2018-10-02       Impact factor: 5.922

Review 2.  Chemical transformation of xenobiotics by the human gut microbiota.

Authors:  Nitzan Koppel; Vayu Maini Rekdal; Emily P Balskus
Journal:  Science       Date:  2017-06-23       Impact factor: 47.728

3.  Design, Synthesis, and Activity Evaluation of Novel N-benzyl Deoxynojirimycin Derivatives for Use as α-Glucosidase Inhibitors.

Authors:  Fanxin Zeng; Zhongping Yin; Jiguang Chen; Xuliang Nie; Ping Lin; Tao Lu; Meng Wang; Dayong Peng
Journal:  Molecules       Date:  2019-09-11       Impact factor: 4.411

Review 4.  Plant Glycosides and Glycosidases: A Treasure-Trove for Therapeutics.

Authors:  Kassiani Kytidou; Marta Artola; Herman S Overkleeft; Johannes M F G Aerts
Journal:  Front Plant Sci       Date:  2020-04-07       Impact factor: 5.753

Review 5.  Human Gut Microbiota and Drug Metabolism.

Authors:  Archana Pant; Tushar K Maiti; Dinesh Mahajan; Bhabatosh Das
Journal:  Microb Ecol       Date:  2022-07-23       Impact factor: 4.192

Review 6.  Recent advances in the development of covalent inhibitors.

Authors:  Hyunsoo Kim; Yoon Soo Hwang; Mingi Kim; Seung Bum Park
Journal:  RSC Med Chem       Date:  2021-05-04

7.  Visualization of Active Glucocerebrosidase in Rodent Brain with High Spatial Resolution following In Situ Labeling with Fluorescent Activity Based Probes.

Authors:  Daniela Herrera Moro Chao; Wouter W Kallemeijn; Andre R A Marques; Marie Orre; Roelof Ottenhoff; Cindy van Roomen; Ewout Foppen; Maria C Renner; Martina Moeton; Marco van Eijk; Rolf G Boot; Willem Kamphuis; Elly M Hol; Jan Aten; Hermen S Overkleeft; Andries Kalsbeek; Johannes M F G Aerts
Journal:  PLoS One       Date:  2015-09-29       Impact factor: 3.240

8.  1,6-Cyclophellitol Cyclosulfates: A New Class of Irreversible Glycosidase Inhibitor.

Authors:  Marta Artola; Liang Wu; Maria J Ferraz; Chi-Lin Kuo; Lluís Raich; Imogen Z Breen; Wendy A Offen; Jeroen D C Codée; Gijsbert A van der Marel; Carme Rovira; Johannes M F G Aerts; Gideon J Davies; Herman S Overkleeft
Journal:  ACS Cent Sci       Date:  2017-07-13       Impact factor: 14.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.